The significance of 5′‐nucleotide phosphodiesterase isozymes in the diagnosis of liver carcinoma

Lu, Huajun; Chen, C; Sze, Pui-Ka; Ming, Tan; Chiang, Kuo‐Hwa; Ting, Chin-Chung; Pan, Lang; Liu, T Y; Yiu, CY

doi:10.1002/ijc.2910260106

Cited by 7 publications

(2 citation statements)

References 2 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from latent métas tasés. liver cell regeneration may contribute false positive results which arc seen in 8% of patients with cirrhosis and 13% of those with hepatitis [93,96], GGT is almost as sensitive as the fast moving isoenzyme of AP and is a useful screening test for liver métastasés [97], More controversial is the use of GGT isoenzymes. A variant (band 1) has been reported in the serum of patients with hepatocellular carci noma independent of disease stage, with a sensitivity of 55% and a specificity of 97% [36,98,99],…”

Section: Liver Métastasés and Hepatomamentioning

confidence: 99%

“…High molecular weight (fast moving) AP isoenzyme correlates well with the presence of liver métastases, and appears in serum due, in part, to local biliary stasis [27,28,30,91,92], Several large scries involving patients with primary and secondary liver cancer [93][94][95][96] have shown that 5'-nucleotide phospho diesterase isoenzyme V has a sensitivity of 88% in the detection of hepatoma, and a sim ilar sensitivity in detecting patients with he patic métastasés. Abnormal values for a-fetoprotein were only found in 40% of the cases, and the enzyme test was especially valuable in the remaining 60%.…”

Section: Liver Métastasés and Hepatomamentioning

confidence: 99%

See 1 more Smart Citation

Serum Enzymes and Enzyme Profiles in the Diagnosis of Liver and Biliary Tract Disease

MacNamara¹,

Goldberg²

1985

Dig Dis

View full text Add to dashboard Cite

Section: Liver Métastasés and Hepatomamentioning

confidence: 99%

Section: Liver Métastasés and Hepatomamentioning

confidence: 99%

Serum Enzymes and Enzyme Profiles in the Diagnosis of Liver and Biliary Tract Disease

MacNamara¹,

Goldberg²

1985

Dig Dis

View full text Add to dashboard Cite

5′-Nucleotide phosphodiesterase isozyme-V as a marker for liver metastases in breast cancer patients

Tsou

Creech

Inouye

et al. 1984

Cancer

View full text Add to dashboard Cite

A 2‐year prospective study testing 258 breast cancer patients for the presence of 5′‐nucleotide phosphodiesterase isozyme‐V (5′‐NPD‐V) as a marker for liver metastases was undertaken. Despite the difficulty associated with such a study in obtaining data from biopsy (only 12 patients) and autopsy (only 18 patients), the 5′‐NPD‐V test correctly predicted confirmed liver metastases in 39 of 41 patients (95%). Of this group, 25 patients had abnormal liver scans at the time the 5′‐NPD‐V test was positive (64%). In 11 of 39 patients 5′‐NPD‐V was found positive before liver scans. In the majority of patients, 5′‐NPD‐V fluctuated between positive and negative during follow‐up. While such transiently positive values may be related to treatment, they should be interpreted conservatively as liver proliferation until confirmed otherwise. Throughout the 2‐year study only seven patients with nonmalignant hepatic diseases had consistent positive values (2.7%). As an indicator of liver metastases 5′‐NPD‐V is more specific than other liver function tests. It is also important to note that 14 patients received early chemotherapy because attention was directed toward the diagnosis of liver metastases by this test.

show abstract

Flow cytometric DNA and 5′-nucleotide phosphodiesterase in endometrium

Tsou

Hong

Varello

et al. 1985

Cancer

View full text Add to dashboard Cite

One hundred endometrium specimens have been studied with flow cytometry for DNA analysis (FCDA) and a proliferative enzyme marker, 5'-nucleotide phosphodiesterase (5'-NPD). FCDA data showed that aneuploidy was present in only 5 of 40 cancer specimens. However, with corrected histograms, a higher DNA value was observed in the G2/M (6%) of all cancer compared with noncancer specimens (4%). Thus, FCDA can be a useful diagnostic aid for endometrial cancer. The determination of 5'-NPD was done with a quenching method based on the use of 5'-(5-iodo-3-indoxyl)-thymidine phosphodiester as a substrate and 4,6-diamidino-2-phenylindole for DNA. This method could qualitatively define which population of the cell cycle had a higher enzyme level and also quantitatively gave the enzyme units per cell. It was found that 12.5% of all cancer specimens had 5'-NPD activity in the Go/GI cells and 87.5% in the S and/ or G2/M cells, whereas in the noncancer specimens 5'-NPD was found in 28.5% of the C0/GI cells and 71.5% of the specimens had 5'-NPD in the S and/or G2/M cells. Furthermore, the concentration of 5'-NPD was found to be five times higher in the G2/M cells of the cancer specimens than that in the noncancer specimens. However, in the hyperplasia specimens, the activity was only two times higher in the same cell cycle fraction than in the normal specimens. The results of this investigation provided for the first time evidence that this exonuclease activity alters in the cell cycle fractions and that a decrease in the enzyme activity in Co/CI cells and an increase in G2/M cells may be a useful marker for neoplastic development in human endometrial cancer.

show abstract

The significance of 5′‐nucleotide phosphodiesterase isozymes in the diagnosis of liver carcinoma

Cited by 7 publications

References 2 publications

Serum Enzymes and Enzyme Profiles in the Diagnosis of Liver and Biliary Tract Disease

Serum Enzymes and Enzyme Profiles in the Diagnosis of Liver and Biliary Tract Disease

5′-Nucleotide phosphodiesterase isozyme-V as a marker for liver metastases in breast cancer patients

Flow cytometric DNA and 5′-nucleotide phosphodiesterase in endometrium

Contact Info

Product

Resources

About